Selinexor is the first oral selective inhibitor of nuclear export compound tested for cancer treatment. Selinexor has demonstrated a safety therapy profile with broad antitumor activity against solid and hematological malignancies in phases 2 and 3 clinical trials (#NCT03071276, #NCT02343042, #NCT02227251, #NCT03110562, and #NCT02606461). Although selinexor shows promising efficacy, its primary adverse effect is high-grade thrombocytopenia.
View Article and Find Full Text PDFWe present a low-resolution density-based scoring scheme for selecting high-quality models from a large pool of lesser quality models. We use pre-configured decoy data sets that contain large numbers of models with different degrees of correctness to evaluate the performance of the strategy. We find that the scoring scheme consistently identifies one of the highest quality models for a wide variety of target structures, resolution ranges, and noise models.
View Article and Find Full Text PDF